|
 |
|
|||||||
|
|||||||||
© 2004 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System
A 12-week proof-of-concept trial in patients with type 2 diabetes
1 Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
2 Turku University Central Hospital, Turku, Finland
3 Novo Nordisk A/S, Bagsvaerd, Denmark
4 Karolinska Institutet at Danderyds Sjukhus, Stockholm, Sweden
Address correspondence and reprint requests to K. Hermansen, MD, Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark. E-mail: kjeld.hermansen{at}aas.auh.dk
OBJECTIVE—To compare the glycemic control of inhaled insulin via the AERx insulin diabetes management system (iDMS) with that of subcutaneous (SC) insulin, both combined with NPH insulin at bedtime, in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—The AERx iDMS uses a liquid insulin formulation to achieve flexible precise mealtime dosing (with increments corresponding to 1 IU administered subcutaneously) and ensures insulin delivery only when the breathing technique is optimal. This trial in patients with type 2 diabetes compared the glycemic control (HbA1c) achieved by inhaled insulin administered via AERx iDMS with that using SC insulin. This was a randomized, 12-week, open-label, parallel, multicenter, multinational trial in 107 nonsmoking patients with type 2 diabetes (mean age 59 years, mean duration of diabetes 11.9 years). Patients were randomized to receive either inhaled fast-acting human insulin via AERx iDMS immediately before meals or SC fast-acting human insulin administered 30 min before meals, both in combination with evening NPH insulin.
RESULTS—Baseline and demographic characteristics were similar between the two groups. There was no statistically significant difference in HbA1c between the AERx and SC groups after 12 weeks of treatment (7.84 ± 0.77 vs. 7.76 ± 0.77%, P = 0.60). Fasting serum glucose was significantly lower in the AERx group compared with the SC group by the end of the trial (8.9 ± 3.8 vs. 10.8 ± 3.7 mmol/l, P = 0.01) with a similar NPH dose in the two groups (0.23 vs. 0.23 IU/kg, P = 0.93). There were no statistically significant differences between the two groups in the intra-subject variability of fasting or prandial blood glucose increment. Adverse events were similar in the two groups. No major safety concerns were raised during the trial.
CONCLUSIONS—In patients with type 2 diabetes, preprandial inhaled insulin via AERx iDMS is as effective as preprandial SC insulin injection in achieving glycemic control with similar tolerability.
Abbreviations: FBG, fasting blood glucose • FSG, fasting serum glucose • iDMS, insulin diabetes management system • PFT, pulmonary function test • SC, subcutaneous • TEAE, treatment emergent adverse event
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, K. M. Stettler, D. W. Neal, M. Scott, L. Bowen, W. Wilson, C. H. Hobbs, C. Leach, T. R. Strack, and A. D. Cherrington Inhalation of Human Insulin Is Associated with Improved Insulin Action Compared with Subcutaneous Injection and Endogenous Secretion in Dogs J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1258 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, A. D. Cherrington, P. Williams, D. W. Neal, M. Scott, L. Bowen, W. Wilson, C. H. Hobbs, C. Leach, M.-c. Kuo, et al. Inhalation of Human Insulin (Exubera) Augments the Efficiency of Muscle Glucose Uptake In Vivo Diabetes, December 1, 2006; 55(12): 3604 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ceglia, J. Lau, and A. G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med, November 7, 2006; 145(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellary and A. H Barnett Review: Inhaled insulin: overcoming barriers to insulin therapy? The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 103 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Rave, L. Nosek, A. de la Pena, M. Seger, C. S. Ernest II, L. Heinemann, R. P. Batycky, and D. B. Muchmore Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro Diabetes Care, October 1, 2005; 28(10): 2400 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J Hendra Review: Diabetes and insulin therapy in older people The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Hollander, L. Blonde, R. Rowe, A. E. Mehta, J. L. Milburn, K. S. Hershon, J.-L. Chiasson, and S. R. Levin Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes: Results of a 6-month, randomized, comparative trial Diabetes Care, October 1, 2004; 27(10): 2356 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Heinemann and T. Heise Review: Current status of the development of inhaled insulin The British Journal of Diabetes & Vascular Disease, September 1, 2004; 4(5): 295 - 301. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |